Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Brigida Anna MaioranoMauro Francesco Pio MaioranoDomenica LorussoEvaristo MaielloPublished in: Cancers (2021)
The identification of biomarkers with a predictive role for ICIs' efficacy is mandatory. Moreover, genomic and immune profiling of OC might lead to better treatment options and facilitate the design of tailored trials.